{"preliminary_commentary":{"by_channel":{"bluesky_thread":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"MyeloMATCH","nct_id":"NCT06577441","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=myelomatch-nct06577441. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR, CRL, or CRh at the end of cycle 6 may cross-over to Regimen 2. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.","label":"Regimen 1 (ASTX727)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive ASTX727 PO QD on days 1-5 and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.","label":"Regimen 2 (ASTX727, enasidenib)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-03-01","type":"ESTIMATED"},"conditions":["Myelodysplastic Syndrome"],"enrollment":{"count":54,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection"],"type":"PROCEDURE"},{"name":"Bone Marrow Aspiration","otherNames":[],"type":"PROCEDURE"},{"name":"Bone Marrow Biopsy","otherNames":["Biopsy of Bone Marrow","Biopsy, Bone Marrow"],"type":"PROCEDURE"},{"name":"Decitabine and Cedazuridine","otherNames":["ASTX 727","ASTX-727","ASTX727","C-DEC","CDA Inhibitor E7727/Decitabine Combination Agent ASTX727","Cedazuridine/Decitabine Combination Agent ASTX727","Cedazuridine/Decitabine Tablet","DEC-C","Inaqovi","Inqovi"],"type":"DRUG"},{"name":"Enasidenib","otherNames":["AG 221","AG-221","AG221","CC-90007 Free Base"],"type":"DRUG"}],"last_update":"2026-11-04","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-03-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Complete response (CR) rate","timeFrame":"Up to 4 cycles of treatment"}],"references":[],"start_date":{"date":"2025-06-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)","url":"https://clinicaltrials.gov/study/NCT06577441"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/myelomatch-nct06577441"}